Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325)

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 2, 2011, Pages 360-368

  Dehing Oberije, Cary ^a   Aerts, Hugo ^a   Yu, Shipeng ^c   De Ruysscher, Dirk ^a   Menheere, Paul ^b   Hilvo, Mika ^d,e   Van Der Weide, Hiska ^a   Rao, Bharat ^c   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SIEMENS CORPORATE RESEARCH   (United States)

^d UNIVERSITY OF TAMPERE   (Finland)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Blood biomarker; Chemotherapy; NSCLC; Prognosis; Prognostic model; Radiotherapy

Indexed keywords

AREA UNDER THE CURVES; BASELINE MODELS; BLOOD BIOMARKER; BLOOD SAMPLES; C-REACTIVE PROTEINS; CARCINOEMBRYONIC ANTIGEN; CLINICAL DATA; CURATIVE INTENT; EXTENDED MODEL; GROSS TUMOR VOLUME; LACTATE DEHYDROGENASE; LEAVE-ONE-OUT; LEAVE-ONE-OUT CROSS VALIDATIONS; MULTIVARIATE MODELS; NON SMALL CELL LUNG CANCER; NSCLC; OSTEOPONTIN; PATIENT POPULATION; POSITIVE LYMPH NODES; PROGNOSIS; PROGNOSTIC MODEL; PROSPECTIVE STUDY; RADIOTHERAPY ALONE; RECEIVER OPERATING CHARACTERISTICS; WORLD HEALTH ORGANIZATION;

BIOLOGICAL ORGANS; BIOMARKERS; BLOOD; CARBONIC ANHYDRASE; CELLS; CHEMOTHERAPY; DISEASES; FORECASTING; PATIENT MONITORING; TUMORS;

RADIOTHERAPY;

C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; GEMCITABINE; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; NAVELBINE; OSTEOPONTIN; TUMOR MARKER;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOXIA; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; C-REACTIVE PROTEIN; CARBONIC ANHYDRASES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; KERATIN-19; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 80052810391     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.06.011     Document Type: Article

References (41)

1. A. Vulto, M. Louwman, and P. Rodrigus Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988-2002 Radiother Oncol 78 2006 131 137 (Pubitemid 43344171)
2. D. Ball, J. Smith, and A. Wirth Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy Int J Radiat Oncol Biol Phys 54 2002 1007 1013 (Pubitemid 35292611)
3. J.D. Bradley, N. Ieumwananonthachai, and J.A. Purdy Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma Int J Radiat Oncol Biol Phys 52 2002 49 57 (Pubitemid 34041565)
4. C. Dehing-Oberije, D. De Ruysscher, and H. van der Weide Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy Int J Radiat Oncol Biol Phys 70 2008 1039 1044 (Pubitemid 351308062)
5. M.D. Brundage, D. Davies, and W.J. Mackillop Prognostic factors in non-small cell lung cancer: A decade of progress Chest 122 2002 1037 1057
6. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 J Clin Oncol 22 2004 330 353 (Pubitemid 41095099)
7. S. Firat, R.W. Byhardt, and E. Gore Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 54 2002 357 364 (Pubitemid 35286798)
8. Chemotherapy for non-small cell lung cancer Non-small Cell Lung Cancer Collaborative Group Cochrane Database Syst Rev 2000:CD002139
9. K. Basaki, Y. Abe, and M. Aoki Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume Int J Radiat Oncol Biol Phys 64 2006 449 454 (Pubitemid 43083431)
10. M. Werner-Wasik, R.S. Swann, and J. Bradley Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 70 2008 385 390
11. L. Zhao, B.T. West, and J.A. Hayman High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer Int J Radiat Oncol Biol Phys 68 2007 103 110 (Pubitemid 46589842)
12. M.J. Solan, and M. Werner-Wasik Prognostic factors in non-small cell lung cancer Semin Surg Oncol 21 2003 64 73 (Pubitemid 37237415)
13. C. Dehing-Oberije, S. Yu, and D. De Ruysscher Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 74 2009 355 362
14. J. Wulfkuhle, V. Espina, and L. Liotta Genomic and proteomic technologies for individualisation and improvement of cancer treatment Eur J Cancer 40 2004 2623 2632 (Pubitemid 39487084)
15. L. Boldrini, V. Donati, and M. Dell'Omodarme Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer Br J Cancer 93 2005 453 457 (Pubitemid 43080020)
16. V. Donati, L. Boldrini, and M. Dell'Omodarme Osteopontin expression and prognostic significance in non-small cell lung cancer Clin Cancer Res 11 2005 6459 6465 (Pubitemid 41338982)
17. J. Kaminska, M. Kowalska, and B. Kotowicz Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - An independent prognostic factor Oncology 70 2006 115 125 (Pubitemid 43760337)
18. M.I. Koukourakis, A. Giatromanolaki, and E. Sivridis Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis Br J Cancer 89 2003 877 885 (Pubitemid 37175811)
19. Q.T. Le, E. Chen, and A. Salim An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers Clin Cancer Res 12 2006 1507 1514
20. M. Orditura, F. De Vita, and G. Catalano Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis J Interferon Cytokine Res 22 2002 1129 1135 (Pubitemid 36051185)
21. N. Songur, B. Kuru, and F. Kalkan Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer Tumori 90 2004 196 200 (Pubitemid 38745608)
22. T. Muley, H. Dienemann, and W. Ebert CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients Anticancer Res 24 2004 1953 1956 (Pubitemid 38954616)
23. J.L. Pujol, O. Molinier, and W. Ebert CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a meta-analysis in 2063 patients Br J Cancer 90 2004 2097 2105 (Pubitemid 38869712)
24. D.E. Swinson, J.L. Jones, and D. Richardson Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer J Clin Oncol 21 2003 473 482 (Pubitemid 46613490)
25. D. De Ruysscher, R. Wanders, and E. van Haren HI-CHART: A phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 71 2008 132 138 (Pubitemid 351491406)
26. Maastricht Radiation Oncology, The Netherlands. Biobank Lung Cancer. Storing blood and protein of patients with lung cancer. NLM identifier: NCT00573040. ClinicalTrials.gov Web site. Bethesda, MD: National Library of Medicine. Available from: URL: http://clinicaltrials.gov/show/NCT00181519. Accessed January 11, 2010.
27. S. Senan, D. De Ruysscher, and P. Giraud Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer Radiother Oncol 71 2004 139 146 (Pubitemid 38521181)
28. Maastricht Radiation Oncology, The Netherlands. Radiotherapy for NSCLC to an individualized MLD (BRONC MLD). NLM identifier: NCT00573040. ClinicalTrials.gov Web site. Bethesda, MD: National Library of Medicine. Available from: URL: http://clinicaltrials.gov/show/NCT00573040. Accessed December 28, 2009.
29. A. van Baardwijk, S. Wanders, and L. Boersma Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer J Clin Oncol 28 2010 1380 1386
30. Maastricht Radiation Oncology, The Netherlands. Concurrent chemo-radiation for NSCLC to an individualized MLD. NLM identifier: NCT00572325. ClinicalTrials.gov Web site. Bethesda, MD: National Library of Medicine. Available from: URL: http://clinicaltrials.gov/show/NCT00572325. Accessed December 28, 2009.
31. N. Cristianini, and J. Shaw-Taylor An introduction to support vector machines and other kernel-based learning methods 2000 Cambridge University Press Cambridge
32. J.C. Platt Probabilities for SV machines A.J. Smola, P. Bartlett, B. Scholkopf, Advances in large margin classifiers 2000 MIT Press Cambridge
33. S. Hammarstrom The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 1999 67 81 (Pubitemid 29265523)
34. A.M. Ballesta, R. Molina, and X. Filella Carcinoembryonic antigen in staging and follow-up of patients with solid tumors Tumour Biol 16 1995 32 41
35. C. Nieder, U. Nestle, and D. Ukena Tumor markers as prognostic factors in non-small-cell bronchial carcinoma Strahlenther Onkol 171 1995 587 593
36. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867 (Pubitemid 36019639)
37. K. Krysan, J.M. Lee, and M. Dohadwala Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance J Thorac Oncol 3 2008 107 110 (Pubitemid 351323182)
38. B.J. Rollins Inflammatory chemokines in cancer growth and progression Eur J Cancer 42 2006 760 767
39. D.D. Sin, and S.F. Man Systemic inflammation and mortality in chronic obstructive pulmonary disease Can J Physiol Pharmacol 85 2007 141 147 (Pubitemid 46996112)
40. J.D. Cox, T.F. Pajak, and S. Asbell Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials Int J Radiat Oncol Biol Phys 27 1993 493 498 (Pubitemid 23331113)
41. P. Goldstraw, J. Crowley, and K. Chansky The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714 (Pubitemid 47357522)